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T  cell leukemias may be induced by exposing adult C57BL/6 mice to fractionated 
x  radiation  (four  170-rad  doses)  or  by  intrathymic  inoculation  of the  radiation 
leukemia  virus  (RadLV), 1 originally isolated  from a  radiation-induced  leukemia  (1). 
As early as  10 d  after  termination  of the leukemogenic treatment,  preleukemic cells 
appear  in the bone marrow and in the thymus  (2),  and  10-18 wk later,  80-100% of 
the animals develop overt lymphomas (3,  4). 
In  a  previous  study  (5)  we  investigated  the  in  vitro  induction  of cell-mediated 
immunity against  radiation- and RadLV-induced leukemias and found that coculti- 
vation  of normal  syngeneic  splenocytes  with  inactivated  tumor  cells  resulted  in  a 
considerable  proliferative  response,  although  cytotoxicity  was  not  generated.  To 
generate  anti-tumor  cytotoxic  T  lymphocytes  (CTL)  in  vitro,  it  was  essential  to 
preimmunize  (prime)  the spleen cell donor with the corresponding stimulator tumor 
cells.  The cytotoxicity was  induced  by,  and  directed  at,  virally  associated  antigens 
expressed  on  RadLV-induced,  but  absent  in  radiation-induced,  primary thymomas 
(5-7). 
Although mice that received a leukemogenic treatment (and, therefore, are expected 
to eventually develop tumors)  are deprived of a  demonstrable anti-tumor immunity, 
we explored the possibility that their lymphocytes are primed and thus may become 
cytotoxic upon in vitro stimulation  with the corresponding tumor cell.  Although we 
failed to demonstrate  anti-tumor cytotoxicity under such circumstances,  we noticed 
that  splenocytes from RadLV-injected,  but  not  irradiated,  mice could suppress  the 
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generation  of  anti-tumor  CTL  in  a  syngeneic  mixed  lymphocyte  tumor  culture 
(MLTC)  with splenocytes derived from preimmunized  (primed) donors. 
The data presented here suggest that the suppression is specific, is mediated by T 
cells, and is not apparent in mice exposed to fractionated radiation. 
Materials  and  Methods 
Mice and Tumors.  Female C57BL/6 and BALB/c mice aged 5-6 wk of age at the start of the 
experiments were employed. Cell line 136.5 was established from a RadLV-induced C57BL/6 
thymoma and  was  generously provided by Dr.  M.  Haas  from The  Weizmann Institute of 
Science, Rehovot, Israel. The  136.5 cells release high titers of leukemogenic RadLV into the 
culture supernate (8) and express virus-related antigenicity on their surface membrane (5, 9). 
The  line was maintained  in  RPMI-1640  medium  supplemented with  10%  fetal calf serum 
(FCS) (Biolab, Jerusalem, Israel) and antibiotics. 
Leukemogenic Treatment.  RadLV leukemogenesis was induced by intrathymic inoculation of 
C57BL/6  mice with  20  /~1 of a  24-h-old  136.5  supernate  as described elsewhere (1).  X-ray 
leukemogenesis was  induced by exposing C57BL/6  mice to whole-body irradiation in  four 
weekly doses of 170 rad as described elsewhere (1). The leukemogenic animals were designated 
RadLV/BL and x-ray/BL, respectively. 
In vivo priming.  3 ×  106 heavily irradiated (9,000  rad)  136.5 cells were inoculated subcuta- 
neously into both flanks of C57BL/6  mice (designated 136.5/BL).  Primed lymphocytes were 
prepared from spleens of 136.5/BL animals 10-14 d after 136.5 inoculation. 
Unidirectional Mixed Lymphocyte Culture (MLC) and ML TC.  Single-cell suspensions of normal 
C57BL/6,  136.5/BL, RadLV/BL, and x-ray/BL splenocytes or mixtures thereof were coculti- 
vated in  microplates or in tubes with heavily irradiated  136.5  cells (9,000  rad) or BALB/c 
splenocytes  (3,000  rad)  under  conditions  described  elsewhere  (10).  In  some  experiments, 
RadLV/BL lymphocytes were fractionated on a nylon wool column or treated with anti-Thy- 
1.2 antibodies plus complement (C') as described elsewhere (11,  12), and subsequently added 
to MLTC of 136.5/BL  responding splenocytes and  136.5  stimulator cells. The  MLTC were 
incubated for 3 d  (in rnicroplates) and for 6 d  (in tubes) in a humidified 5% CO2 atmosphere 
at 37°C. 
Concanavalin A  (ConA)-induced Stimulation.  Normal C57BL/6,  136.5/BL, RadLV/BL, and x- 
ray/BL splenocytes or mixtures thereof were incubated in microplates with 10% FCS-RPMI- 
1640 medium that contained 2.5 #g/ml ConA (type III; Sigma Chemical Co., St. Louis, Mo.) 
for 3 d as described above. 
DNA Synthesis Measurement.  Microplate cultures were pulsed with  1 /~Ci [3H]thymidine for 
the last 16 h and subsequently precipitated on fiberblass filters with a multiple sample harvester 
(Titertek;  Skatron  A.S.,  Norway).  The  filters  were  air-dried  and  their  radioactivity was 
measured by scintillation counting. The DNA stimulation index (SI) was calculated by dividing 
the counts per minute of test cultures by the counts per minute in control cultures without 
stimulating cells. 
Lymphocyte-mediated Cytotoxicity Assay.  After a  6-d incubation, cells cultured in tubes were 
harvested and their cytotoxic activity was determined using the 51Cr-release  assay as described 
elsewhere (12), with 6 h incubation. The percent specific SlCr release was calculated according 
to the formula: 
r  release in test- spontaneous release  ] 
percent specific release =  [.maximal release -  spontaneous releaseJ  ×  100. 
Cytotoxic activity was also expressed in lyric units (LU)/culture, calculated from the dose- 
response curve according to  the  method of Cerottini  and  Brunner  (13).  1 LU  was  defined 
arbitrarily as the number of viable effector cells required to lyse 30% of 104 51Cr-labeled target 
cells for 6 h at 37°C. 
Results 
Splenocytes derived from  136.5/BL mice, but not from normal C57BL/6 mice, turn 
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induced by and directed at  RadLV-associated antigens expressed on the tumor cell 
membrane  (5).  However,  no  generation  of CTL  was  observed among  lymphocytes 
derived from  RadLV/BL  mice  (4  and  8  wk after  virus  inoculation),  after  in  vitro 
stimulation  with  136.5  cells  (Fig.  1).  In  fact,  the  cytotoxieity  levels  with  such 
lymphocytes  were  much  below  the  background  cytotoxicity conferred  by  normal 
lymphocytes sensitized with  136.5 cells. 
When splenocytes from RadLV/BL  were added to MLTC  comprised of 136.5/BL 
splenocytes  and  inactivated  136.5  cells,  a  marked  suppression  of anti-136.5  CTL 
generation was observed (Fig. 2). The suppressive effect was most efficient with a  1:1 
RadLV/BL:  136.5/BL ratio (-80% suppression), but was also evident with a  1:5 ratio 
(65%  suppression)  and  a  1:10  ratio  (40%  suppression).  Equal  numbers  of normal 
C57BL/6 splenocytes did not inhibit the cytotoxic response. Suppression was equally 
efficient when  mediated by  RadLV/BL,  4,  6  or  8  wk after  virus  inoculation.  The 
suppressive effect was  already evident  in splenocytes of RadLV/BL  5  d  after virus 
inoculation,  and  after  -2  wk,  it  reached  the  maximal  level of suppression  which 
remained constant during the entire leukemogenic process (Fig. 3). 
Treatment  of RadLV/BL  splenocytes with  anti-Thy-l.2  antibodies and  C' corn- 
~a 
20 
IO0;I 
Effector:target  rotio 
FIG.  1.  Cytotoxic activity of splenocytes stimulated in vitro with 136.5 cells. Target cells: 136.5. 
(D) Normal C57BL/6;  (~7) 136.5/BL; and RadLV/BL 4 (LX) and 6 (O) wk after virus inoculation. 
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FIG. 2.  RadL\T/BL splenocytes suppress generation of syngeneic anti-!.36.5 CTL. 25 ×  10  a 136.5/ 
BL lymphocytes were mixed with increasing numbers of normal C57BL/6 (open bars) and RadLV/ 
BL splenocytes 4 (hatched bars), 6 (dotted bars) and 8 (dark bars) wk after viral inoculation. The 
mixtures were cocuhivated with 2.5 ×  106 inactivated 136.5 cells for 6 d and assayed for cytotoxicity 
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Fro.  3.  Kinetics  of appearance  of suppressor  splenocytes  in  RadLV/BL,  25  X  106  136.5/BL 
splcnocytes were mixed with  25  X  10  s RadLV/BL  splenocytes taken at various times  after virus 
inoculation.  T~e  mixtures  were cocuhivated  with  2.5  x  106 inactivated  136.5  cells  for 6  d  and 
assayed for cytotoxicity with 51Cr-labeled target cells. 
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FIG.  4.  Effect of fractionation on a nylon wool column  and treatment with  anti-Thy-l.2  plus C' 
on suppressive activity  of Radgg/Bg  splenocytes.  136,5/BL  sp]enocytes were mixed with  equal 
number of normal  C57BL,  RadLV/BL,  nylon  wool-fractionated  RadLV/BL,  and  RadLV/BL 
treated with anti-Thy 1.2 and C'. The mixtures were cocultivated with inactivated 136.5  cells for 6 
d  and their cytotoxic activity toward SlCr-labeled  136.5  targets was measured. 
pletely abolished their capacity to  suppress  the cytotoxic stimulation of 136.5/BL 
splenocytes by 136.5 cells (Fig. 4). On the other hand, fractionation on a nylon wool 
column did not alter the suppressive effect. 
In contrast with their unresponsiveness to stimulation with syngeneic 136.5 cells, 
RadLV/BL splenocytes could be readily sensitized by allogeneic (BALB/c) lympho- 
cytes (Fig, 5). Such splenocytes had no suppressive effect on generation ofallocytotoxic 
T  cells in MLC of C57BL/6 lymphocytes responding to BALB/c stimulating cells 
(Fig. 5). 
Splenocytes taken from x-ray/BL mice 4 wk after termination of irradiation did 
not generate cytotoxieity after eocuhivation with 136.5 cells (Fig. 6). However, 136.5 
priming of x-ray/BL mice and subsequent in vitro sensitization of their splenocytes 
with  136.5 cells,  led to generation of anti-136.5  CTL, almost as efficiently as with 
splenocytes from 136.5/BL controls (Fig, 6). In contrast, RadLV/BL splenocytes did 
not turn cytotoxic after MLTC with 136.5 stimulating cells, even after in vivo priming 
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FIG. 5.  RadLV/BL splenocytes do not suppress generation of allocytotoxic cells. C57BL/6 and 
RadLV/BL splenocytes were mixed in equal numbers and cocuhivated with inactivated BALB/c 
lymphocytes. Cytotoxicity was  measured  after  6  d  with  51Cr-labeled ConA-induced  BALB/c 
lymphoblasts. 
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Fzc. 6.  Cytotoxic activity of lymphocytes from unprimed C57BL/6 and 136.5/BL, RadLV/BL, 
and  x-ray/BL mice after  in  vitro stimulation  with  136.5 cells. Target  cells: 136.5. (0)  Normal 
C57BL/6; (O)  136.5/BL; (A) RadLV/BL (4 wk after virus inoculation); (~) RadLV/BL primed 
with 136.5 (4 wk after virus inoculation); (I) x-ray/BL (4 wk after last irradiation dose); and (I-'1) 
x-ray/BL primed with 136.5 cells (4 wk after last irradiation dose). 
The addition  of x-ray/BL effector splenocytes  to MLTC  comprised  of 136.5/BL 
responding lymphocytes and inactivated  136.5 stimulating cells did not abolish CTL 
generation in  1:10,  1:5, and even  1:1 x-ray/BL: 136.5/BL ratios  (Fig.  7).  Under such 
circumstances,  splenocytes  from  RadLV/BL  strongly  suppressed  CTL  generation 
(Fig. 2). 
The  proliferative  responses  of  splenocytes  derived  from  C57BL/6,  136.5/BL, 
RadLV/BL,  and  x-ray/BL  mice,  or  mixtures  thereof,  to  syngeneic,  allogeneic,  or 
mitogenic stimulation were also examined. As shown in Table I, all four lymphocyte 
populations  responded  vigorously to a  BALB/c or ConA stimulus.  Stimulation  by 
136.5 cells was considerably low,  but  evident  among normal, x-ray/BL, and  136.5/ 
BL  splenocytes,  with  a  higher  SI  in  the  latter.  However,  RadLV/BL  splenocytes, 1478  RADIATION LEUKEMIA VIRUS-INDUCED LEUKEMOGENESIS 
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FIG,  7.  X-ray/BL splenocytes  do not suppress  generation of syngeneic anti-136.5  CTL. 136.5/BL 
splenocytes were mixed with increasing numbers of splenocytes  from normal C57BL/6 (open bars) 
or x-ray/BL mice 4  (hatched bars)  and 6  (dark bars)  wk after termination of the leukemogenic 
treatment. The mixtures were cocuhivated 6 d with inactivated 136.5 and assayed  for cytotoxicity 
toward 51Cr-labeled 136.5 targets. 
TABLE  I 
Effect of Splenocytes  fiom RadL V/  BL or X-ray  / BL on DNA Synthesis in Individual and Mixed Cultures 
of Normal C57BL/6 and 136.5/BL Lymphocytes after Syngeneic, Allogeneic, and ConA Stimulation 
Stimulator  Responder I  Responder II 
(1.5 ×  10  5  (1.5 ×  l0  B 
ceils)  cells)  136.5 (1.5 ×  104  BALB/c (l.5 ×  104 
cells)  cells)  ConA (2.5 ~g/ml) 
cpm  SI  cpm  SI  cpm  SI 
C57BL/6  --  5,706*  6.9  15,059  26.7  35,702  37.7 
(827)$  (564)  (947) 
136.5/BL  --  9,301  9.2  14,169  27.3  45,859  34.9 
(l,011)  (519)  (1,314) 
RadLV/BL  --  1,171  1.2  16,195  24.1  26,198  31.3 
(976)  (672)  (837) 
X-ray/BL  --  4,782  5.7  13,298  22.2  28,724  31.6 
(839)  (599)  (909) 
C57BL/6  C57BL/6  10,731  7.3  22,113  31.5  51,910  42.1 
(1,470)  (702)  (1233) 
C57BL/6  RadLV/BL  1,330  1.4  18,094  26.3  35,307  36.4 
(950)  (688)  (970) 
C57BL/6  X-ray/BL  8,768  7.1  19,082  29.0  39,891  32.6 
(1,235)  (658)  (1224) 
136.5/BL  136.5/BL  8,177  7.4  20,959  30.2  44,533  38.0 
(1,106)  (694)  (1172) 
136.5/BL  RadLV/BL  1,079  1.4  19,034  26.4  29,058  33.4 
(771)  (721)  (870) 
136.5/BL  X-ray/BL  9,471  9.5  17,013  25.7  34,057  35.7 
(997)  (662)  (954) 
* Mean uptake of [aH]thymidine at day 3 of culture. 
$ Background counts per minute in cultures without stimulator cells. 
although  stimulated  strongly  by BALB/c  lymphocytes or ConA,  did  not  respond  to 
136.5  stimulation. 
When  RadLV/BL  lymphocytes  were  mixed  in  equal  numbers  with  normal EITAN YEFENOF, AMALIA MEIDAV, AND ELI KEDAR  1479 
C57BL/6 or 136.5/BL lymphocytes, DNA synthesis after stimulation with 136.5 cells 
was inhibited. Such inhibition was not observed in mixtures of C57BL/6 or 136.5/BL 
splenocytes  with  C57BL/6  or  x-ray/BL  splenocytes.  However,  stimulation  by 
BALB/c  cells  or  by  ConA  was  not  inhibited  by  x-ray/BL  nor  by  RadLV/BL 
splenocytes. 
Discussion 
A  large  variety  of experimental  tumors  possess  tumor-specific  transplantation 
antigens capable of evoking cell-mediated immune responses in vitro (13,  14).  Yet, 
such tumors can grow progressively in vivo and kill their hosts, which, generally are 
devoid of effective anti-tumor immunity. 
Because various types of humoral and cellular immune reactivities have been shown 
to be regulated by suppressor cells (15, 16), it has been proposed that tumor rejection 
in  vivo  may  be  hampered  by  host-suppressor  cells  capable  of interfering with  a 
potential anti-tumor immunity (I 7). 
Suppressor cells associated with animal and human malignancies have been char- 
acterized  in  many systems  (18).  Kirchner et  al.  (19)  have  described  a  suppressor 
macrophage in  C57BL/6  mice that  bore murine sarcoma  virus-induced sarcomas, 
that could nonspecifically abrogate a  variety of humorai and cell-mediated immune 
responses.  Nonspecific  immunosuppression  mediated  by  T  cells  was  found  in 
C57BL/6 mice that  bore 3LL Lewis lung carcinoma  (20). Fujimoto et al.  (21)  and 
Takei et al.  (22)  have described a  T  cell population in  mice that  bore progressive 
tumors, which could specifically suppress anti-tumor cell-mediated immune reactivity. 
Although  the existence of suppressor ceils in tumor-bearing individuals has been 
widely documented, little is known about their role during premalignant stages. It is 
therefore difficult to conclude whether suppressor cells are indeed a  necessary com- 
ponent of the neoplastic process, promoting tumor cell proliferation, or if they merely 
represent a secondary consequence of the growing tumor (23). 
Cegalowski and Friedman (24) have found that mice infected with Friend leukemia 
virus show a suppressed antibody response to sheep erythrocytes (SRBC), long before 
overt leukemia can be detected. Similarly, Peled and Haran-Ghera (25)  have shown 
that  intrathymic  inoculation  of RadLV  into C57BL/6  animals  markedly reduced 
their  plaque-forming  ability  after  immunization  with  SRBC,  shortly  after  virus 
inoculation. However, cell-mediated immunity to allogeneic cells was not affected. 
Because it was possible to generate anti-tumor cytotoxic responses during MLTC 
with  136.5/BL lymphocytes responding  to the  RadLV-infected  136.5  cells  (5),  we 
examined  the  possibility that  anti-tumor cytotoxic manifestation  may  be demon- 
strated also in lymphocytes of RadLV-inoculated mice during the latency period. It 
was found that splenocytes of RadLV/BL mice neither lyse 136.5  cells directly nor 
after in vitro stimulation with the tumor. Moreover, even splenocytes of RadLV/BL 
animals  that  had  been preimmunized with  136.5  cells did  not  respond with  DNA 
synthesis, nor did they turn cytotoxic upon cocultivation with 136.5 cells. 
The inability of RadLV/BL Iymphocytes to respond in MLTC with  136.5  cells 
prompted us to explore the question whether it was  a  result of a  general  immune 
unresponsiveness of mice undergoing a leukemogenic process, or that activation of a 
suppressive mechanism in such mice inhibited a  potential anti-tumor immune reac- 
tivity. Therefore, 136.5/BL lymphocytes, known to respond in syngeneic MLTC, were 
mixed with RadLV/BL splenocytes and cocultivated with inactivated  136.5  stimu- 1480  RADIATION LEUKEMIA VIRUS-INDUCED LEUKEMOGENESIS 
lator cells. A strong suppression in generation of anti-136.5 cytotoxicity was observed 
under  such  circumstances.  The  suppressive  effect of RadLV/BL  splenocytes was 
specific to syngeneic anti-136.5 responsiveness, because RadLV/BL splenocytes could 
vigorously  respond  to  BALB/c  cells  with  extensive  DNA  synthesis  followed  by 
generation  of allocytotoxic cells.  Moreover,  allosensitization  of normal  C57BL/6 
lymphocytes was not inhibited, but was somehow augmented, by RadLV/BL splen- 
ocytes. The increase in both the  proliferative and  cytotoxic alloresponsiveness was 
probably a result of lymphocyte clones in the added RadLV/BL spleen cells that also 
responded  to  the  allostimulus,  as  addition  of equal  number  of normal  C57BL/6 
lymphocytes to the MLC also resulted with increased proliferation and cytotoxicity. 
Similarily, RadLV/BL splenocytes stronglyresponded with DNA synthesis when 
stimulated  with  ConA  and  did  not  interfere with  normal  C57BL/6  lymphocytes 
responding to the mitogen. 
The  abrogation  of the  inhibitory effect in  RadLV/BL  splenocytes treated with 
anti-Thy-l.2 plus C', and its retention after fractionation on a  nylon wool column 
indicated  that  the suppression was  mediated by a  nonadherent  T  cell population. 
Such cells, taken from animals that bore progressively growing tumors were shown to 
inhibit anti-tumor cell-mediated immunity in a specific manner (18). 
RadLV leukemogenesis involves a  latency period of several months (3).  However, 
the  suppressive  effect  of RadLV/BL  splenocytes  was  evident  very  early  in  the 
leukemogenic process. It already reached its full capacity 2 wk after viral inoculation 
and  remained  constant  during  the  entire  preleukemic  phase,  as  well  as  in  mice 
developing overt lymphomas. 
The emergence of overt lymphomas in C57BL/6 mice inoculated with RadLV is 
preceded  by  the  induction  of preleukemia  cells  shortly  after  virus  injection  (2). 
Interestingly, the appearance of the suppressor cell population in the spleens of such 
mice coincides with  the  development of preleukemic cells  in  the  marrow  and  the 
thymus, which  are  detectable  as  soon  as  10  d  after virus  inoculation  (2).  Further 
experimentation should be performed to  find out  whether the suppressive effect is 
induced by preleukemic cells or merely by the virus inoculum. 
RadLV was originally isolated from a C57BL/6 thymoma induced by fractionated 
irradiation (26).  Therefore it was believed for many years that x ray leukemogenesis 
involves  activation  of latent  endogenous  echotropic  C-type  virus,  which  in  turn 
induces T  cell leukemias  (27,  28).  This hypothesis was opposed by recent findings 
showing that, in contrast with the strong expression of C-type virus antigenicity on 
RadLV-induced tumors, the majority of x-ray-induced lymphomas are virus negative 
(7, 23). In a previous study (5), we reported that generation of cell-mediated immunity 
in vitro toward C57BL/6 T  cell lymphomas was dependent on membrane-associated 
viral  antigenic  expression  of the  tumor  cell.  It  was  therefore interesting  to  know 
whether splenocytes of mice exposed to  fractionated irradiation  will  also  suppress 
syngeneic anti-136.5  cytotoxic responses.  In  contrast  to  RadLV/BL  lymphocytes, 
splenocytes of x-ray/BL mice added to MLTC of 136.5/BL lymphocytes responding 
to  136.5  cells  did  not  inhibit  generation  of anti-tumor cytotoxicity. Furthermore, 
136.5 cells could stimulate DNA synthesis in x-ray-BL splenocytes, and lymphocytes 
from x-ray/BL animals that had been preimmunized with  136.5 cells could generate 
anti-tumor cytotoxicity when coculativated with  136.5 cells. 
These  results  could  be  explained  by  the  possibility  that  antigenically  different EITAN YEFENOF, AMALIA MEIDAV, AND ELI KEDAR  1481 
recombinant viruses may act in individual x-ray-induced leukemogenic processes (29). 
However, the lack of viral antigenicity and  immunogenicity in primary radiogenic 
leukemias,  as opposed to the  virus expression and  the efficient immunogenicity in 
virally induced primary tumors (5, 7, 30), does not favor involvement of viral etiology 
in x-ray leukemia induction. The difference demonstrated here between RadLV and 
x-ray-induced leukemogenesis with regard to the immunological pattern during the 
preleukemic latency further supports this notion. 
Based on the findings reported herein, we hypothesize that  RadLV-induced leu- 
kemogenesis is concomitant with expression of virus-related antigenicity capable of 
inducing specific immune suppression that sustains the proliferation of the RadLV- 
infected  tumor  cells  in  spite  of a  potential  anti-tumor  immunity,  x-ray-induced 
leukemogenesis does  not  involve viral  etiology and  therefore is  not  immunogenic. 
Under such circumstances tumor progression occurs without immune stimulation of 
the host and, therefore, suppressor cells are not developed. 
Studies were begun  in  our laboratory to test  this  hypothesis and  to  answer  the 
question of whether the suppressor ceils described herein play a significant role in the 
leukemogenic process and to what degree they are essential for tumor progression. 
Summary 
Adult  C57BL/6 mice exposed to fractionated irradiation or inoculated with  the 
radiation leukemia virus (RadLV), develop high incidence (80-100%) of lymphatic 
leukemias within 3-6 mo. RadLV-induced lymphomas can elicit cytotoxic responses 
in vitro in lymphocytes of preimmunized syngeneic mice, a reaction that is dependent 
on  the expression of membrane-associated  viral  antigenicity.  As  soon  as  5  d  after 
RadLV inoculation, and during the entire leukemogenic process, suppressor T  cells 
are detectable in the spleen that are capable of specifically abrogating generation of 
syngeneic anti-tumor cytotoxic cells in vitro. Mice exposed to fractionated x irradiation 
do not develop suppressor cells and their splenocytes may be stimulated in vitro to 
generate cytotoxicity toward RadLV-induced leukemias. These findings suggest that 
although  RadLV  has  been  isolated  from  radiation-induced  leukemias,  x-ray- and 
RadLV-induced leukemogenesis do not seem to involve a common viral etiology, and 
that induction of suppressor cells during RadLV leukemogenesis may be essential for 
tumor progression. 
Received  for publication 4June 1980 and in revised  form 21 July 1980. 
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